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Abstract
Facioscapulohumeral muscular dystrophy (FSHD), a common form of muscular
dystrophy, is caused by a genetic mutation that alters DUX4 gene expression.
This mutation contributes to significant skeletal muscle loss. Although it is suggested that cardiac muscle may be spared, people with FSHD have demonstrated
autonomic dysregulation. It is unknown if baroreflex function, an important regulator of blood pressure (BP), is impaired in people with FSHD. We examined if
baroreflex sensitivity (BRS) is blunted in patients with FSHD. Thirty minutes of
resting BP, heart rate, and cardiovagal BRS were measured in 13 patients with
FSHD (age: 50 ± 13 years, avg ± SD) and 17 sex- and age-matched controls (age:
47 ± 14 years, p > 0.05). People with FSHD were less active (Activity Metabolic
Index, AMI) (FSHD: 24 ± 30; controls: 222 ± 175 kcal/day; p < 0.001) but had
a similar body mass index compared with controls (FSHD: 27 ± 4; controls:
27 ± 4 kg/m2; p > 0.05). BRSup (hypertensive response), BRSdown (hypotensive
response), and total BRS were similar between groups (BRSup: FSHD: 12 ± 8;
controls: 12 ± 5 ms/mmHg; BRSdown: FSHD: 10 ± 4; controls: 13 ± 6 ms/mmHg;
BRS: FSHD: 14 ± 9; controls: 13 ± 6 ms/mmHg; p > 0.05). Mean arterial pressure
was similar between groups (FSHD: 96 ± 7; controls: 91 ± 6mmHg). Individuals
with FSHD had an elevated heart rate compared with controls (FSHD: 65 ± 8;
controls: 59 ± 8 BPM; p = 0.03), but when co-varied for AMI, this relationship disappeared (p = 0.39). These findings suggest that BRS is not attenuated in people
with FSHD, but an elevated heart rate may be due to low physical activity levels,
a potential consequence of limited mobility.
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I N T RO DU CT ION

Facioscapulohumeral muscular dystrophy (FSHD) is the
third most common type of muscular dystrophy, present
in about 1/20,000 of the population (Mavrogeni et al.,
2018). It is caused by the reactivation of the double homeobox protein 4 (DUX4) in skeletal muscle, which is
silenced after early embryonic development in most organs (Lim et al., 2020). The expression of the DUX4 gene
influences many complex pathways, eventually leading to
skeletal muscle cell death (Bosnakovski et al., 2008; Geng
et al., 2012). Thus, individuals with FSHD exhibit progressive skeletal muscle atrophy and functional declines in
strength and movement (Emmrich et al., 2005; Wang &
Tawil, 2016) which present first in the face, shoulder girdle, and upper-arm regions, and then progress to the lower
extremities (Statland & Tawil, 2016; Wang & Tawil, 2016).
Although not observed by all (Tawil et al., 2015; Trevisan
et al., 2006), several studies have noted cardiac and autonomic dysfunction in people with FSHD (Berlit & Stegaru-
Hellring, 1991; Finsterer et al., 2005; Laforêt et al., 1998;
Stevenson et al., 1990). For example, electrocardiogram
abnormalities (Berlit & Stegaru-Hellring, 1991; Finsterer
et al., 2005; Laforêt et al., 1998; Stevenson et al., 1990),
abnormal ventricular hypertrophy (Finsterer et al., 2005),
and cardiomyopathy (Laforêt et al., 1998) were amongst
the cardiac symptoms exhibited by patients with FSHD.
Both cardiac and autonomic dysfunctions are of clinical
relevance and linked to hypertension (Lucini et al., 2002),
risk of future cardiovascular events (Ormezzano et al.,
2008), and heart failure (La Rovere et al., 2001; Thames
et al., 1993). It is unclear, however, whether the dysfunction noted in these studies was a result of the genetic mutation or of deconditioning, a consequence of the physical
disability that manifests from FSHD.
Previous work has demonstrated that individuals with
FSHD exhibit exercise intolerance (Vera et al., 2022),
driven by loss of skeletal muscle (Preston et al., 1999);
are at higher risk for developing sarcopenic obesity (Vera
et al., 2020); and are usually less physically active than
people without FSHD as a result of their disability (Vera
et al., 2020, 2021). This decrease in activity leads to physical deconditioning, which is known to contribute to the
acceleration of cardiovascular disease (CVD) development
through attenuated autonomic function (Coupé et al.,
2009; Maher et al., 2017). The potential increased risk of
CVD associated with autonomic dysfunction through low
levels of cardiorespiratory fitness could suggest a higher
risk of CVD in adults with FSHD.
The baroreflex, a critical regulatory component of the
autonomic nervous system (ANS), is a neurally mediated, negative feedback mechanism that is an important
contributor to blood pressure (BP) homeostasis. Earlier

ANSELMO et al.

studies demonstrated that arterial baroreflex sensitivity
(BRS) primarily contributes to the short-term regulation
of BP (Lanfranchi & Somers, 2002), while others suggest a
strong contribution to long-term BP regulation (Lohmeier,
2001; Lohmeier et al., 2004). Baroreflex sensitivity has
been observed to be low in physically deconditioned individuals (Hughson & Shoemaker, 2015), as well as in
hypertensive patients at high risk of developing CVD
(Gordin et al., 2016). Whether BRS is attenuated in adults
with FSHD, however, remains unknown. Understanding
BRS in adults with FSHD is a critical step in characterizing
the CVD risk that may be associated with FSHD, thereby
facilitating early interventions and treatment strategies
to improve cardiovascular health and a healthy lifespan
in people with FSHD. Thus, the objective of the present
study was to examine if BRS is impaired in patients with
FSHD. We hypothesized that BRS would be attenuated in
the FSHD group as compared with controls.

2
2.1

|

METHODS

|

Participants

Thirteen adults with FSHD (age 50 ± 13 years; four females, nine males; one Hispanic, twelve European
American) and seventeen healthy age-  and sex-matched
individuals (age 47 ± 14 years; five females, twelve males;
one of African descent, two of Asian descent, one Hispanic
and thirteen European Americans) were recruited to
participate in this study. Inclusion criteria consisted of:
≥18 years of age and no prior history of cardiovascular,
pulmonary, orthopedic, or neuromuscular disorders other
than FSHD; female participants were excluded if they
were currently pregnant or breastfeeding (Dewey, 1997;
Lof et al., 2005). Menstrual cycle was not controlled for
in the female participants. This study is part of a larger
clinical study (Vera et al., 2021). Participants provided
written informed consent prior to any procedures being
performed. The study was approved by the University of
Minnesota Institutional Review Board and conducted in
accordance with the Declaration of Helsinki.

2.2

|

Study design

Participants completed one study visit at which they
completed a general medical questionnaire to rule out
cardiovascular, neuromuscular, pulmonary or orthopedic disorders. They also completed a physical activity
questionnaire to calculate their activity metabolic index
score (AMI) (Richardson et al., 1994). To determine the
functional ability level and severity of FSHD symptoms,
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people with FSHD completed a Facioscapulohumeral
Muscular Dystrophy Health Index questionnaire
(FSHD-HI) (Johnson et al., 2012). These surveys were
scored on a scale of 0 to 100, where 100 reflects the
worst subjective level of disease severity. Females were
required to provide a urine sample prior to study procedures to ensure they were not pregnant. Participants
fasted and had no caffeine for at least 12 h prior to the
study.

2.3

|

Procedures

After written informed consent, height and weight were
obtained, participants rested in a supine position and
were instrumented with non-invasive devices to measure heart rate (HR) and BP. Data was collected over
30 min of rest.
Heart rate was measured with a three-lead electrocardiogram (ECG) (ADInstruments), and BP was recorded via
a small cuff placed on the annular or middle finger of the
participant's non-dominant hand (Human non-invasive
blood pressure [NIBP], ADInstruments). Manual brachial
BP was obtained to calibrate the NIBP system. Heart rate
variability and BRS were calculated from the ECG as well
as the ECG and BP measurements, respectively.

2.4

|

Data analysis

Data was sampled and recorded at 1000 samples/s by a
high-performance data acquisition device (PowerLab,
ADInstruments). Cardiovascular variables were recorded continuously throughout the 30-min rest period.
Spontaneous cardiovagal BRS was quantified using the
sequence method (Bertinieri et al., 1985). The sequence
method identifies three or more consecutive beats where
systolic BP (SBP) and R-R interval (RRI) concurrently increase or decrease by at least 1 mmHg or 4 ms, respectively
(Wessel et al., 2020). Sequences of three or more beats
changing in the same direction were only included in the
calculation if the correlation coefficient was greater than
0.7 (i.e., r > 0.7) (Parati et al., 2000; Smyth et al., 1969).
Sequences were manually inspected to exclude artifacts.
Baroreflex sensitivity to hypertensive stimuli (BRSup) and
hypotensive stimuli (BRSdown) were quantified, as they
have been reported to correlate with the phenylephrine
pressor (hypertensive stimuli) stimuli and nitroprusside
depressor (hypotensive) baroreflex test sensitivities, respectively (Rudas et al., 1999; Watkins et al., 1995). Thus,
BRSup is the average of the slopes where SBP and RRI increase simultaneously, and BRSdown is the average of the
slopes where SBP and RRI decrease simultaneously.
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Heart rate variability was calculated with LabChart software (ADInstruments). Heart rate variability was reported
as the average RRI, standard deviation of normal-normal
intervals (SDNN), and root mean square of successive differences between normal heartbeats (RMSSD) for time-
domain analyses, and as high frequency (HF) power for
the frequency domain analysis. The SDNN is the standard
deviation of intervals between heartbeats with ectopic
beats removed (i.e., normal intervals), while RMSSD is the
root mean square of successive normal intervals. High frequency power is a reliable estimation of parasympathetic
activity and ranges between frequencies of 0.15–0.4 Hz
(Pomeranz et al., 1985). The low frequency (LF) domain,
although controversial, represents a combination of parasympathetic activity, sympathetic activity and baroreflex
function (Randall et al., 1991). Thus, because of the non-
specificity of LF power, this variable, along with LF/HF
power, were not included in the analyses.

2.5

|

Statistical analysis

Data was evaluated for normality using the Shapiro-Wilk
test prior to analysis. Data that was not normally distributed was subsequently analyzed with nonparametric
methods. Demographic characteristics of the participants
were analyzed and reported as means and standard deviations. Two-sample independent t-tests were used to compare age, body mass index (BMI), HR, SBP, mean arterial
pressure (MAP), RMSSD, RRI, SDNN, and BRSdown between FSHD and CTL. The Mann-Whitney U-test was
used to compare activity metabolic index (AMI), diastolic
blood pressure (DBP), HF power, BRSup, and total BRS
between these groups. To determine if BMI, AMI and use
of antihypertensive or antidepressant medication influenced autonomic and cardiovascular variables, analyses
were repeated including these factors as covariates.
For the HRV analyses (i.e., RMSSD, RRI, SDNN, and
HF power), data from one individual with FSHD was excluded due to an arrhythmia. In all analyses, outliers were
identified using the interquartile rule with a multiplier of
2.2 (Hoaglin et al., 1986). Following identification of outliers, one additional individual with FSHD was excluded
from HF power analysis, and three individuals (all FSHD
participants) were excluded from BRSdown analysis.
Thus, the final participant numbers were n = 17 for CTL
and n = 12 for FSHD for RMSSD, RRI, and SDNN; n = 17
for CTL and n = 11 for FSHD for HF power; and n = 17 for
CTL and n = 10 for FSHD for BRSdown. In all other analyses, n = 17 for CTL and n = 13 for FSHD. To evaluate effect
size, Cohen's d was calculated for hemodynamic and HRV
variables. For all statistical analyses, SPSS v27.0 (IBM) was
used. The ⍺ level for significance was set at 0.05.

4 of 10

3

|

|   

ANSELMO et al.

R E S U LTS

Control and FSHD participants were similar in age, BMI,
and the use of anti-hypertensive and antidepressant medications (p > 0.05), but AMI was lower in the FSHD group
(p < 0.001, Table 1).
Neither BRSup (d = 0.05, p = 0.9, Figure 1a), BRSdown
(d = 0.57, p = 0.17, Figure 1b), nor total BRS (d = 0.21,
p = 1.0, Figure 1c) differed between FSHD and CTL
groups. In addition, an inverse relationship was observed
between BMI and BRS when groups were combined
(r = −0.56, p < 0.001, Figure 2). However, BRS was not
associated with AMI (r = 0.06, p = 0.77). Similarly, HRV
measures were similar between groups (RRI: d = 0.64,
p = 0.10, Figure 3a; SDNN: d = 0.02, p = 0.39, Figure
3b; RMSSD: d = 0.15, p = 0.70, Figure 3c; HF: d = 0.16,
p = 0.78, Figure 3d). Body mass index was also inversely
associated with RMSSD (r = −0.44, p = 0.02) and trended
to be associated with HF power (r = −0.37, p = 0.06) when
groups were combined. In addition, no associations were
observed when groups were separated (p > 0.05).
Heart rate and BP data are located in Table 1. Heart
rate was significantly higher in the FSHD group than in
the CTL group (d = 0.09, p = 0.02, but when co-varying
for AMI, HR was similar between groups (p = 0.38). In
addition, there was a trend for HR to be inversely associated with AMI, indicating that individuals with elevated HR were less physically active (r = −0.34, p = 0.08).
Systolic BP (d = 0.22, p = 0.56), DBP (d = 0.59, p = 0.86),
and MAP (d = 0.68, p = 0.08) were slightly but not significantly elevated in FSHD. The FSHD-HI score was not

correlated with any cardiovascular or autonomic measures (p > 0.05).

|

4

DISC USSION

Although previous literature suggests individuals with
FSHD demonstrate autonomic dysfunction, novel findings
from this study reveal that BRS and HRV were similar in
people with FSHD compared with controls. We did, however, observe an elevated HR in people with FSHD compared with controls that was mitigated when co-varying
for physical activity levels. Further, regardless of physical
activity or disease state, we observed a strong relationship
between BMI, baroreflex function and HRV, indicating
that individuals with a lower BMI have a greater ability
to modulate blood pressure and demonstrate greater parasympathetic activity, respectively.

4.1 | Cardiovascular function and
baroreflex sensitivity in adults with FSHD
Cardiac abnormalities have been observed in animal
models and humans with FSHD. This is the first study,
however, to investigate if BRS is altered in adults with
FSHD. Indeed, studies investigating a relationship between any type of muscular dystrophy and BRS are
sparse. In a mouse model of Duchenne muscular dystrophy, Chu et al. (2002). observed an attenuated BRS,
while Sabharwal et al. (2015) reported that autonomic

FSHD

Control

Female (n)

4

5

Male (n)

9

12

Age (range, years)

50 ± 13 (31–72)

47 ± 14 (25–75)

BMI (kg/m2)

27 ± 4

27 ± 4

AMI (kcal/day)

24 ± 30

222 ± 175*

FSHD-HI (au)

29 ± 13

—

Anti-hypertensive medications (n)

1

2

Anti-depressant medications (n)

3

4

Heart rate (bpm)

65 ± 8

59 ± 8*

Systolic BP (mmHg)

124 ± 11

122 ± 11

Diastolic BP (mmHg)

80 ± 8

76 ± 8

Mean arterial BP (mmHg)

96 ± 7

91 ± 6

Note: Control and FSHD participants were similar in age, BMI, and the use of medications (p > 0.05).
Activity metabolic index (AMI) was lower in the FSHD group (p < 0.001) and heart rate (beats/min, bpm)
was greater in the FSHD group (p = 0.03). Data is presented as mean ± SD.
Abbreviations: au, arbitrary units; BMI, body mass index; BP, blood pressure; FSHD-HI,
Facioscapulohumeral muscular dystrophy health index.
*Significantly different than controls, p < 0.001.

T A B L E 1 Participant characteristics
and baseline cardiovascular data
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F I G U R E 2 Relationship between body mass index (BMI) and
baroreflex sensitivity (BRS) (r = −0.56, p < 0.001)

F I G U R E 1 Cardiovagal baroreflex sensitivity. (a) BRSup:
“up” cardiovagal baroreflex sensitivity, (b) BRSdown: “down”
cardiovagal baroreflex sensitivity, (c) Total BRS. BRS measures
were similar between controls and FSHD (p > 0.05). Black circles
indicate the mean value for each group

dysfunction preceded pathological cardiac hypertrophy
in their mouse model of muscular dystrophy. Cardiac abnormalities in adults with FSHD that have been observed
include left ventricular myocardial thickening (Finsterer
et al., 2005) and abnormal ECG readings in the form of
biatrial P-waves, impaired sinoatrial node and atrioventricular node conduction, as well as atrial flutter or fibrillation (Laforêt et al., 1998; Stevenson et al., 1990). In
addition, Ducharme-Smith et al. demonstrated that in
104 individuals with genetically confirmed FSHD, the
most common cardiac abnormalities were a right bundle branch block and mitral valve prolapse (Ducharme-
Smith et al., 2021).

Although several studies report cardiac and autonomic
involvement in patients with FSHD (Berlit & Stegaru-
Hellring, 1991; Finsterer et al., 2005; Laforêt et al., 1998;
Stevenson et al., 1990), no relationship with disease severity has been observed. The lone study to observe an association between disease severity and cardiac implications
was conducted by Berlit and colleagues, where 20 patients
with several types of muscular dystrophy were observed
to have ECG abnormalities and hypertrophic cardiomyopathy (Berlit & Stegaru-Hellring, 1991). The authors concluded that patients with progressive muscular dystrophy
are more likely to exhibit cardiac symptoms as compared
to those with stable muscular dystrophy. Collectively,
with the majority studies demonstrating cardiac dysfunction, one might expect an attenuated BRS in FSHD,
which would suggest impaired ability to modulate BP. Our
findings of intact autonomic function in FSHD were surprising given that cardiac dysfunction can contribute to
(Martinka et al. 2005) or precede baroreflex dysfunction
(Sabharwal et al., 2015).
In the current study, BRStotal was slightly, but not
significantly, elevated in FSHD compared with CTL, but
when partitioned into BRSup and BRSdown, only BRSup
was minimally elevated in FSHD than CTL. BRSdown
was slightly depressed, albeit not significantly, in FSHD
compared with CTL. The effect size was moderate, indicating the potential for the baroreflex to have a reduced
ability to increase BP from an acute decline (Rudas et al.,
1999) in FSHD. However, it is important to distinguish between the clinical significance of BRSup and BRSdown.
BRSdown generally provides less insight into HTN and
CVD risk than BRSup, as BRSup indicates the ability to
decrease BP when it acutely increases. Further, BRSup,
but not BRSdown, was found to be a significant predictor

6 of 10

|   

ANSELMO et al.

F I G U R E 3 (a) R-R interval (RRI)
(FSHD, n = 12), (b) standard deviation of
N-N intervals (SDNN), (FSHD, n = 12),
(c) root mean square of successive
differences between normal heartbeats,
(RMSSD) (FSHD n = 12), (d) high
frequency power (HF), (FSHD, n = 11).
CTL, control; FSHD, facioscapulohumeral
dystrophy. HRV measures were similar
between controls and FSHD (p > 0.05).
Black circles indicate the mean value for
each group

of the propensity for developing fatal arrhythmias after a
heart attack in dogs 3–4 weeks after a myocardial infarction (Billman et al., 1982). Thus, an attenuated BRSup may
be linked to the future development of fatal arrhythmias,
whereas a small impairment in BRSdown may not be
clinically meaningful. Regardless, there was not a significant impairment in either BRSup or BRSdown in adults
with FSHD. Our observations of a relationship between
BRS and BMI when groups are combined, coupled with
the lack of association between FSHD-HI and autonomic
function measures, could suggest that autonomic dysregulation may be more strongly linked to body composition
than to having FSHD or to the level of disability experienced by people with FSHD.

4.2 | Heart rate variability in adults
with FSHD
Altered HRV parameters are associated with increased
risk of CVD and sudden cardiac events (Cygankiewicz
& Zareba, 2013). Previous studies suggest an attenuated
HRV in adults with FSHD (Della Marca et al., 2010). For
example, Della Marca et al. observed that a patient's clinical severity of FSHD was inversely correlated with HF
power and positively associated with LF power (Della
Marca et al., 2010). These authors suggest that their findings indicate that those with more severe FSHD have lower
parasympathetic output and higher sympathetic output,
compared to less-affected FSHD patients. In addition,
lower HRV has been observed in patients suffering from
Duchenne and Becker muscular dystrophy (Ammendola
et al., 2006; Lanza et al., 2001; Yotsukura et al., 1995). This

dysfunction has been described as an increase in sympathetic output and a decrease in parasympathetic output
as compared with healthy controls (Lanza et al., 2001;
Yotsukura et al., 1995). While decreased HF power and
increased LF power was observed in the muscular dystrophy group of these studies, it is important to note that
LF power is not a marker of sympathetic output and has
considerable influence from parasympathetic activity and
the baroreflex (Goldstein et al., 2011; Randall et al., 1976).
Thus, results from these previous studies should be considered with caution.
Notably, Tsuji and colleagues observed a significant
association between decreased HF power and cardiovascular mortality in older adults (Tsuji et al., 1994, 1996).
Since decreased parasympathetic drive has the potential
to increase an individual's risk of developing CVD, these
findings may indicate increased risk for cardiac events in
individuals with FSHD (Grassi, 2009; Thayer et al., 2010).
Our findings, however, are not consistent with these previous studies. In the current study, FSHD patients exhibited similar HF power, RMSSD and SDNN to their control
counterparts. While both sympathetic and parasympathetic activity contribute to SDNN, HF power and RMSSD
are vagally mediated and indicate that parasympathetic
function is similar between the two groups in our study
(Shaffer & Ginsberg, 2017). Besides one FSHD participant taking a prescribed anti-hypertensive medication,
our FSHD cohort was relatively healthy without cardiac
dysfunction, which could be the reason BRS was not attenuated in adults with FSHD in this study. The lack of
attenuation in BRS and HRV in adults with FSHD supports the notion that autonomic function is likely spared
in adults with FSHD, without existing co-morbidities.

ANSELMO et al.
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|

Physical deconditioning in FSHD

Physical deconditioning as a result of limited mobility and physical activity can lead to numerous health-
related outcomes such as negative changes in body
composition, decreased sensitivity of blood pressure
regulation, as well as the occurrence of dysglycemia and
dyslipidemia (Maher et al., 2017), contributing to an elevated CVD risk profile (Nash et al., 2005). In the present
study, the FSHD group exhibited lower activity levels
than the control group with an AMI of 24 ± 30 kcal/day
(FSHD) compared to 222 ± 175 kcal/day (CTL). Vera
et al. observed that individuals with FSHD experience
exercise intolerance (Vera et al., 2022), likely a contributing factor to deconditioning in this group. Further,
several studies have reported that BRS decreases following periods of physical deconditioning (Convertino
et al., 1990; Convertino & Fritsch, 1992), although
these studies focused on prolonged bed rest rather than
disease-related limited mobility.
Elevated resting HR can be a marker of sympathetic
overdrive and is commonly associated with increased risk
of CVD and cardiac events (Zhang et al., 2016). Albeit in
normal ranges, we observed an elevated HR in adults with
FSHD as compared with controls which was no longer
significant when co-varying for physical activity levels.
Collectively, these results suggest an intact autonomic
regulation of BP in this cohort of FSHD, and the observed
elevated HR could likely be mitigated with increasing
physical activity levels in adults with FSHD.

4.4

|

Limitations

It is important to consider limitations when interpreting
results of the current study. First, the sample size was
small, with a considerably lower number of female participants, precluding any sex-difference analysis. Of note,
however, effect sizes were also considerably low, indicating that regardless of sample size, the difference in means
was minimal. Menstrual cycles were also not controlled
for in the study, as two participants were post-menopausal
and one pre-menopausal. While BRS has been reported
to fluctuate throughout the menstrual cycle, we do not
believe this severely impacted our results, due to the
small sample of female participants (Brooks et al., 2012).
Further, a third of the individuals in each group were on
medications that can influence BRS (Broadley et al., 2005;
Vasudev et al., 2011; Watkins & Grossman, 1999) which
could have influenced the results of this study. However,
when co-varied for medications, the outcome of the analysis did not change. It is also important to note that a
similar number of participants in each group were taking
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these prescribed medications. The study participants were
also primarily European American, making the results
less generalizable to other races and ethnicities.

5

|

CONC LUSION

The current study provides evidence that BRS and HRV
in individuals with FSHD are preserved, despite the lower
physical ability indicated by the FSHD-HI. Further, our
observations suggest that a slightly elevated HR in FSHD
may be indicative of physical inactivity or deconditioning, which may put this group at risk for future CVD or
cardiac events, but this could be secondary to FSHD or
overexpression of the DUX4 gene mutation, as we did not
observe alterations in autonomic function in this group.
Clinically, these findings are important because they may
suggest that the greater CVD that previous studies have
observed could be linked to deconditioning in addition
to the misregulation of the DUX4 gene. With this knowledge, we are in a stronger position to suggest therapeutic interventions that would be beneficial to reduce CVD
risk in FSHD. For example, it has been demonstrated that
exercise can lead to significant functional benefits without compromising muscle tissue in patients with FSHD
(Bankolé et al., 2016). Therefore, patients with FSHD
may benefit from increasing physical activity levels both
to optimize functional status and reduce the risk of CVD.
Future research should explore specific exercise recommendations for the FSHD population and their influence
on the cardiovascular risk profile in these individuals.
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